BMC Endocrine Disorders · Aug 20, 2026

One-hour plasma glucose identifies metabolic subgroups in individuals with HbA1c-defined prediabetes and normal fasting and 2-hour glucose

By Ouyang L, Nie Q, Huang Y et al.

BACKGROUND: This study evaluated whether 1-hour postload glucose (1-h PG) identifies distinct metabolic subgroups with differing OGTT-derived β-cell function indices among Chinese adults with HbA1c-defined prediabetes and normal fasting and 2-hour glucose. METHODS: This cross-sectional study included 8,537 Chinese adults undergoing 75-g OGTT and HbA1c testing. Participants were stratified into four glycemic phenotypes based on HbA1c (≥5.7%) and OGTT criteria. Within the HbA1c+/OGTT- subgroup (n=922), individuals were further classified by 1-h PG (cutoff 8.6 mmol/L). β-cell function was assessed using the disposition index (DI). Linear mixed-effects models analyzed glucose and insulin dynamics. RESULTS: Among 3,800 individuals with prediabetes, 24.3% exhibited isolated HbA1c elevation (HbA1c+/OGTT-). Within this discordant subgroup, 51.8% had elevated 1-h PG (≥8.6 mmol/L). The 1-h PG+ subgroup demonstrated lower β-cell function (DI = 40.47), delayed glucose peaks (60 min), impaired early-phase insulin secretion, and greater overall glycaemic exposure, whereas the 1-h PG- subgroup exhibited preserved or enhanced β-cell function (DI = 85.19 vs. 75.56 in NGT, P < 0.001). Multivariable linear regression analysis demonstrated that 1-h PG remained significantly associated with β-cell function after adjustment for age, sex, and HbA1c. CONCLUSIONS: Among individuals with HbA1c-defined prediabetes and normal Fasting and 2-Hour Glucose, 1-hour plasma glucose identifies subgroups with differing metabolic profiles and β-cell function. These findings highlight substantial metabolic heterogeneity within this population. However, given the cross-sectional design of the study, longitudinal investigations are required to determine whether these metabolic differences translate into differences in future diabetes risk and clinical outcomes. TRIAL REGISTRATION: Not applicable.

doi.org/10.1186/s12902-026-02485-7Open accessPubMed 43052968Biomarkers

AgingResearch.News